NanoCor Therapeutics
Chapel Hill
About NanoCor Therapeutics
NanoCor Therapeutics is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF). The company was spun off from Asklêpios BioPharmaceutical, Inc. in November 2005. NanoCor’s initial focus is the commercial development of a non-invasive treatment for CHF. NanoCor’s therapeutic is comprised of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBio’s proprietary Biological NanoParticle (BNP™) and the Self-Complementary Vector technologies, which are derived from human adeno-associated virus vectors (rAAV).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2007)
- Website: nanocorthx.com
- Phone: +1 9199 334 755
Industries & Categories
Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nanocor-therapeutics-2240998 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.